👩⚕️👨⚕️Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis
▪︎GETAID multi🏥 retrospective study
▪︎N=169 pts
▪︎SFCR at weeks 8-14: upadacitinib (55.2%) 🆚️filgotinib (33.3%)🆚️tofacitinib (50%)
▪︎upa was associated with ⬆️ odds of SFCR compared to Filgo